Barclays Trims Acadia Healthcare (NASDAQ:ACHC) Target Price to $91.00

Acadia Healthcare (NASDAQ:ACHC) had its price objective decreased by equities research analysts at Barclays from $100.00 to $91.00 in a research report issued to clients and investors on Thursday, Benzinga reports. The firm presently has an “overweight” rating on the stock. Barclays‘s target price suggests a potential upside of 37.63% from the stock’s previous close.

A number of other equities analysts have also recently issued reports on ACHC. TD Cowen boosted their price objective on shares of Acadia Healthcare from $86.00 to $101.00 and gave the company an “outperform” rating in a research report on Friday, March 1st. Deutsche Bank Aktiengesellschaft upgraded Acadia Healthcare from a “sell” rating to a “hold” rating and set a $70.00 price target on the stock in a report on Thursday, April 25th. Royal Bank of Canada reiterated an “outperform” rating and issued a $94.00 price objective on shares of Acadia Healthcare in a report on Monday, March 4th. Cantor Fitzgerald reissued a “neutral” rating and set a $90.00 target price on shares of Acadia Healthcare in a research note on Tuesday, March 5th. Finally, Stephens raised Acadia Healthcare from an “equal weight” rating to an “overweight” rating and set a $92.00 price target for the company in a research note on Friday, January 5th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and six have assigned a buy rating to the company’s stock. According to MarketBeat.com, Acadia Healthcare has an average rating of “Moderate Buy” and a consensus price target of $89.50.

Acadia Healthcare Trading Down 0.9 %

NASDAQ ACHC opened at $66.12 on Thursday. The stock has a 50-day moving average of $77.13 and a 200-day moving average of $77.61. The company has a current ratio of 0.67, a quick ratio of 0.67 and a debt-to-equity ratio of 0.48. Acadia Healthcare has a 1-year low of $64.74 and a 1-year high of $87.77. The firm has a market cap of $6.11 billion, a PE ratio of -472.29, a price-to-earnings-growth ratio of 2.15 and a beta of 1.31.

Acadia Healthcare (NASDAQ:ACHC) last announced its quarterly earnings data on Wednesday, May 1st. The company reported $0.84 earnings per share for the quarter, beating the consensus estimate of $0.80 by $0.04. Acadia Healthcare had a positive return on equity of 11.56% and a negative net margin of 0.38%. The firm had revenue of $768.10 million during the quarter, compared to the consensus estimate of $779.20 million. During the same quarter in the previous year, the company posted $0.75 earnings per share. The business’s revenue was up 9.1% on a year-over-year basis. As a group, sell-side analysts forecast that Acadia Healthcare will post 3.57 EPS for the current year.

Insider Buying and Selling

In other Acadia Healthcare news, Director Wade D. Miquelon sold 2,203 shares of the firm’s stock in a transaction on Tuesday, March 5th. The stock was sold at an average price of $85.39, for a total transaction of $188,114.17. Following the completion of the transaction, the director now owns 46,074 shares of the company’s stock, valued at $3,934,258.86. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. 2.00% of the stock is owned by insiders.

Hedge Funds Weigh In On Acadia Healthcare

Large investors have recently made changes to their positions in the business. GAMMA Investing LLC bought a new position in Acadia Healthcare during the 4th quarter valued at approximately $26,000. Headlands Technologies LLC bought a new stake in Acadia Healthcare during the 3rd quarter valued at about $25,000. Mather Group LLC. purchased a new position in Acadia Healthcare in the first quarter worth about $48,000. Fifth Third Bancorp grew its holdings in shares of Acadia Healthcare by 25.5% during the fourth quarter. Fifth Third Bancorp now owns 670 shares of the company’s stock valued at $52,000 after buying an additional 136 shares during the last quarter. Finally, DekaBank Deutsche Girozentrale bought a new stake in shares of Acadia Healthcare during the third quarter valued at approximately $96,000.

Acadia Healthcare Company Profile

Acadia Healthcare Company, Inc provides behavioral healthcare services in the United States and Puerto Rico. The company develops and operates acute inpatient psychiatric facilities, specialty treatment facilities comprising residential recovery facilities and eating disorder facilities, comprehensive treatment centers, and residential treatment centers, as well as facilities offering outpatient behavioral healthcare services for the behavioral healthcare and recovery needs of communities.